Search
androgen receptor antagonist; androgen receptor signaling inhibitor (ARSI)
Adverse effects:
- increased risk of cardiovascular events when used in combination with conventional androgen deprivation therapy [1]
Related
androgen or anabolic steroid
androgen receptor; dihydrotestosterone receptor; nuclear receptor subfamily 3 group C member 4 (AR, DHTR, NR3C4)
Specific
apalutamide (Erleada)
bicalutamide (Casodex)
clascoterone (Cassiopea, Breezula, Winlevi)
darolutamide (Nubeqa)
enzalutamide (Xtandi)
flutamide (Eulexin, Niftholide)
nilutamide (Nilandron)
General
receptor antagonist
hormone antagonist
References
- El-Taji O, Taktak S, Jones C, et al.
Cardiovascular Events and Androgen Receptor Signaling Inhibitors in Advanced
Prostate Cancer: A Systematic Review and Meta-Analysis.
JAMA Oncol. 2024 Jun 6:e241549.
PMID: 38842801 PMCID: PMC11157448 (available on 2025-06-06)
https://jamanetwork.com/journals/jamaoncology/fullarticle/2819647